ABSTRACT
Although most veterinarians look at vaccine labels each day, they rarely see them. When practitioners sense a need to read labels, they find that the labeling answers some of their basic questions but that these labels often fail to address many relevant issues. In addition, veterinarians find that the issues addressed are often presented simplistically and that the labels are sometimes just wrong. This article addresses what practitioners need to do to better understand the products most of them use on a daily basis.
Subject(s)
Animal Diseases/prevention & control , Drug Labeling , Vaccines , Animals , United States , Veterinary DrugsSubject(s)
Vaccination/veterinary , Vaccines , Animals , Cats , Dogs , Drug Labeling/standards , Societies , United States , United States Department of Agriculture , Vaccination/adverse effects , Vaccination/standards , Vaccines/administration & dosage , Vaccines/adverse effects , Vaccines/standards , Veterinary MedicineSubject(s)
Cat Diseases/prevention & control , Clinical Protocols , Societies, Medical , Vaccination/veterinary , Vaccines/administration & dosage , Animals , Cat Diseases/epidemiology , Cats , Communicable Disease Control , United States/epidemiology , Vaccination/standards , Vaccines/adverse effects , Vaccines/standardsABSTRACT
Ten trapped Rocky Mountain elk (Cervus elaphus nelsoni) were successfully immobilized with a combination of 500 mg Telazol and 60 mg xylazine hydrochloride (HCl) from 9 July to 25 August 1993 in Custer State Park, South Dakota (USA). Mean (SD) dosages of 2.5 (0.6) mg/kg Telazol and 0.3 (0.1) mg/kg xylazine HCl, respectively, were administered, resulting in a mean (SD) induction time of 4.6 (0.8) min. Induction time varied with weight and dosage. Respiratory rate (breaths/min) increased following injection of Telazol and xylazine HCl and remained elevated or continued to increase through 10 min post-injection and then declined. There were no mortalities in this study. Forty mg of yohimbine HCl was used as an antagonist in eight elk, resulting in a mean (SD) recovery time of 14.0 (9.9) min when administered intravenously (n = 6), and 124.7 (9.5) min when given intramuscularly (n = 2). Recovery time varied with weight and dosage of yohimbine. Elk given 2.1 to 2.6 mg/kg Telazol and 0.1 to 0.3 mg/kg xylazine HCl responded to yohimbine HCl when administered intravenously.
Subject(s)
Anesthetics , Deer/physiology , Immobilization , Sympatholytics/pharmacology , Tiletamine , Xylazine , Yohimbine/pharmacology , Zolazepam , Anesthetics/administration & dosage , Anesthetics/antagonists & inhibitors , Animals , Drug Combinations , Female , Injections, Intramuscular/veterinary , Injections, Intravenous/veterinary , Male , Respiration/drug effects , Sympatholytics/administration & dosage , Tiletamine/administration & dosage , Tiletamine/antagonists & inhibitors , Time Factors , Xylazine/administration & dosage , Xylazine/antagonists & inhibitors , Yohimbine/administration & dosage , Zolazepam/administration & dosage , Zolazepam/antagonists & inhibitorsABSTRACT
The pharmacokinetic properties of butorphanol tartrate were determined in 7 rabbits after IV and SC injection (0.5 mg/kg of body weight). A 2-compartment model (biexponential) best represented the concentration vs time curve after IV injection. The half-life was calculated to be 1.64 hours via IV administration, whereas SC injection resulted in an elimination half-life of 3.16 hours.
Subject(s)
Butorphanol/pharmacokinetics , Rabbits/metabolism , Animals , Butorphanol/administration & dosage , Female , Half-Life , Injections, Intravenous/veterinary , Injections, Subcutaneous/veterinary , Male , Tissue DistributionABSTRACT
The pharmacokinetics of butorphanol tartrate were investigated following intravenous administration of 0.25 mg/kg of body weight to six healthy non-lactating Jersey cows. Three lactating Holstein cows also received 0.045 mg of butorphanol/kg of body weight intravenously to determine the extent and duration of drug transfer into milk. A radioimmunoassay technique was used to measure butorphanol concentrations in plasma and milk. The disposition of butorphanol following intravenous administration was characterized by rapid and extensive distribution followed by a slower elimination phase. Apparent volume of distribution was 4.178 +/- 1.145 (mean +/- SD) 1/kg, mean elimination half-life was 82 min, and clearance was 34.6 +/- 7.7 ml/min/kg. Trace quantities of butorphanol were detected in the cow's milk for up to 36 h following administration. These pharmacokinetic data were compared with pharmacokinetic and pharmacodynamic data for butorphanol in other species and for three other potent opioids in related ruminant species.
